Finally, recent results showing that immunostimulatory RN7SL1 and antigen peptide released in EV by CAR T cells can be operated to enhance an endogenous immune response against tumors opens the possibility that CAR T cells can be used to deliver EV armed with RN7SL1 or RN7SL1 together a peptide antigen of choice [140], provided that the neoantigen is present in the tumor. The gene discussed is RN7SL1; the disease is neoplasm.